US Patent

US9827242 — Method of treatment for mental disorders

Method of Use · Assigned to Sumitomo Dainippon Pharma Co Ltd · Expires 2031-05-23 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating mental disorders, specifically ADHD, using lurasidone or a combination of lurasidone and a D4 receptor agonist.

USPTO Abstract

The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D 4 receptor agonist.

Drugs covered by this patent

lurasidone-hydrochloride (LURASIDONE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2201`	—	lurasidone-hydrochloride
`U-2199`	—	lurasidone-hydrochloride
`U-2199`	—	lurasidone-hydrochloride
`U-2199`	—	lurasidone-hydrochloride
`U-2201`	—	lurasidone-hydrochloride

Patent Metadata

Patent number: US9827242
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-23
Drug substance claim: No
Drug product claim: No
Assignee: Sumitomo Dainippon Pharma Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.